Design Therapeutics Key Executives
This section highlights Design Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Design Therapeutics
(Showing 0 of )
Design Therapeutics Earnings
This section highlights Design Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2023 | 2024-03-19 | $-0.32 | $-0.21 |
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
$3.90
Stock Price
$221.37M
Market Cap
54
Employees
Carlsbad, CA
Location
Financial Statements
Access annual & quarterly financial statements for Design Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $226 |
| Cost of Revenue | $- | $537.00K | $466.00K | $129.00K | $5.00K |
| Gross Profit | $- | $-537.00K | $-466.00K | $-129.00K | $-4.77K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -2112.39% |
| Research and Development Expenses | $44.35M | $57.06M | $48.61M | $24.78M | $6.06M |
| General and Administrative Expenses | $18.03M | $21.13M | $18.98M | $11.05M | $2.50M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $18.03M | $21.13M | $18.98M | $11.05M | $2.50M |
| Other Expenses | $- | $- | $4.29M | $298.00K | $-226.00K |
| Operating Expenses | $62.38M | $78.19M | $67.59M | $35.83M | $8.33M |
| Cost and Expenses | $- | $78.19M | $67.59M | $35.83M | $8.33M |
| Interest Income | $12.79M | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $- | $537.00K | $466.00K | $129.00K | $5.00K |
| EBITDA | $-62.38M | $-66.33M | $-62.84M | $-35.70M | $-8.32M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -3683628.32% |
| Operating Income | $-62.38M | $-78.19M | $-67.59M | $-35.83M | $-8.33M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -3685840.71% |
| Total Other Income Expenses Net | $12.79M | $11.33M | $4.29M | $298.00K | $50.00K |
| Income Before Tax | $-49.59M | $-66.86M | $-63.31M | $-35.53M | $-8.28M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -3663716.81% |
| Income Tax Expense | $- | $-1 | $-4.69M | $-107.56K | $-201.30K |
| Net Income | $-49.59M | $-66.86M | $-58.62M | $-35.53M | $-8.28M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -3663716.81% |
| EPS | $-0.88 | $-1.19 | $-1.05 | $-0.77 | $-0.30 |
| EPS Diluted | $-0.88 | $-1.19 | $-1.05 | $-0.77 | $-0.30 |
| Weighted Average Shares Outstanding | 56.59M | 55.98M | 55.71M | 45.94M | 27.19M |
| Weighted Average Shares Outstanding Diluted | 56.59M | 55.98M | 55.71M | 45.94M | 27.19M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $838.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $33.00K | $20.00K | $31.00K | $142.00K |
| Cost of Revenue | $- | $- | $151.00K | $143.00K | $138.00K | $137.00K | $143.00K | $139.00K | $135.00K | $122.00K | $113.00K | $96.00K | $82.00K | $31.00K | $12.00K | $4.00K | $2.71M | $1.91M | $1.06M | $377.00K |
| Gross Profit | $- | $- | $-151.00K | $-143.00K | $700.00K | $-137.00K | $-143.00K | $-139.00K | $-135.00K | $-122.00K | $-113.00K | $-96.00K | $-82.00K | $-31.00K | $-12.00K | $-4.00K | $-2.67M | $-1.89M | $-1.03M | $-235.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 83.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -8106.06% | -9470.00% | -3322.58% | -165.49% |
| Research and Development Expenses | $12.16M | $11.88M | $10.37M | $9.66M | $10.87M | $13.26M | $17.06M | $15.73M | $14.26M | $14.30M | $11.29M | $8.76M | $7.34M | $8.54M | $5.03M | $3.88M | $2.71M | $1.91M | $1.06M | $377.00K |
| General and Administrative Expenses | $4.54M | $4.37M | $4.53M | $4.60M | $4.11M | $5.57M | $5.53M | $5.92M | $5.14M | $4.89M | $4.34M | $4.61M | $3.79M | $2.80M | $2.66M | $1.80M | $1.19M | $489.00K | $433.00K | $388.00K |
| Selling and Marketing Expenses | $- | $- | $76.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $4.54M | $4.37M | $4.53M | $4.60M | $4.11M | $5.57M | $5.53M | $5.92M | $5.14M | $4.89M | $4.34M | $4.61M | $3.79M | $2.80M | $2.66M | $1.80M | $1.19M | $489.00K | $433.00K | $388.00K |
| Other Expenses | $- | $- | $3.25M | $3.29M | $3.28M | $3.03M | $2.66M | $2.36M | $2.05M | $1.49M | $640.00K | $105.00K | $62.00K | $19.00K | $51.00K | $166.00K | $6.00K | $63.00K | $21.00K | $-40.00K |
| Operating Expenses | $16.69M | $16.25M | $14.89M | $14.26M | $14.98M | $18.82M | $22.60M | $21.65M | $19.39M | $19.19M | $15.64M | $13.37M | $11.13M | $11.34M | $7.69M | $5.68M | $3.86M | $2.38M | $1.46M | $623.00K |
| Cost and Expenses | $16.69M | $16.25M | $15.04M | $14.40M | $15.12M | $18.82M | $22.60M | $21.65M | $19.39M | $19.19M | $15.64M | $13.37M | $11.13M | $11.34M | $7.69M | $5.68M | $3.86M | $2.38M | $1.46M | $623.00K |
| Interest Income | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $129.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $149.00K | $153.00K | $151.00K | $143.00K | $138.00K | $137.00K | $143.00K | $139.00K | $135.00K | $122.00K | $113.00K | $96.00K | $82.00K | $31.00K | $12.00K | $4.00K | $4.00K | $1.00K | $1.46M | $623.00K |
| EBITDA | $-16.55M | $-16.09M | $-14.89M | $-14.26M | $-14.98M | $-18.68M | $-22.46M | $-21.52M | $-19.27M | $-19.08M | $-15.55M | $-13.29M | $-11.04M | $-11.31M | $-7.67M | $-5.68M | $-3.86M | $-2.38M | $21.00K | $-40.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1787.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -11687.88% | -11910.00% | -4719.35% | -438.73% |
| Operating Income | $-16.69M | $-16.25M | $-15.04M | $-14.40M | $-15.12M | $-18.82M | $-22.60M | $-21.65M | $-19.39M | $-19.19M | $-15.64M | $-13.37M | $-11.13M | $-11.34M | $-7.69M | $-5.68M | $-3.86M | $-2.38M | $-1.46M | $-623.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1804.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -11700.00% | -11915.00% | -4719.35% | -438.73% |
| Total Other Income Expenses Net | $3.04M | $3.21M | $3.25M | $3.29M | $3.28M | $3.03M | $2.66M | $2.36M | $2.05M | $1.49M | $640.00K | $105.00K | $62.00K | $19.00K | $51.00K | $166.00K | $6.00K | $63.00K | $21.00K | $-40.00K |
| Income Before Tax | $-13.65M | $-13.04M | $-11.79M | $-11.11M | $-11.84M | $-15.79M | $-19.94M | $-19.29M | $-17.34M | $-17.70M | $-15.00M | $-13.27M | $-11.06M | $-11.32M | $-7.64M | $-5.51M | $-3.85M | $-2.32M | $-1.44M | $-663.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1413.13% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -11681.82% | -11600.00% | -4651.61% | -466.90% |
| Income Tax Expense | $- | $- | $- | $99.72K | $2.49M | $-137.00K | $10.91K | $-2.36M | $-2.18M | $-1.49M | $-640.00K | $-105.00K | $-62.00K | $- | $- | $- | $- | $- | $-1.46M | $-623.00K |
| Net Income | $-13.65M | $-13.04M | $-11.79M | $-11.11M | $-11.84M | $-15.79M | $-19.94M | $-16.94M | $-15.16M | $-16.22M | $-14.36M | $-13.16M | $-11.06M | $-11.32M | $-7.64M | $-5.51M | $-3.85M | $-2.32M | $-1.44M | $-663.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1413.13% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -11681.82% | -11600.00% | -4651.61% | -466.90% |
| EPS | $-0.24 | $-0.23 | $-0.21 | $-0.20 | $-0.21 | $-0.28 | $-0.36 | $-0.30 | $-0.27 | $-0.29 | $-0.26 | $-0.24 | $-0.20 | $-0.21 | $-0.14 | $-0.31 | $-0.14 | $-0.09 | $-0.05 | $-0.02 |
| EPS Diluted | $-0.24 | $-0.23 | $-0.21 | $-0.20 | $-0.21 | $-0.28 | $-0.36 | $-0.30 | $-0.27 | $-0.29 | $-0.26 | $-0.24 | $-0.20 | $-0.21 | $-0.14 | $-0.31 | $-0.14 | $-0.09 | $-0.05 | $-0.02 |
| Weighted Average Shares Outstanding | 56.59M | 56.62M | 56.56M | 56.49M | 56.15M | 55.99M | 55.95M | 55.91M | 55.86M | 55.78M | 55.67M | 55.51M | 55.36M | 55.16M | 55.08M | 17.63M | 27.19M | 27.19M | 27.19M | 27.19M |
| Weighted Average Shares Outstanding Diluted | 56.59M | 56.62M | 56.56M | 56.49M | 56.15M | 55.99M | 55.95M | 55.91M | 55.86M | 55.78M | 55.67M | 55.51M | 55.36M | 55.16M | 55.08M | 17.63M | 27.19M | 27.19M | 27.19M | 27.19M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $22.56M | $21.20M | $26.50M | $298.57M | $2.38M |
| Short Term Investments | $222.91M | $260.60M | $303.89M | $85.50M | $33.71M |
| Cash and Short Term Investments | $245.48M | $281.80M | $330.39M | $384.06M | $36.09M |
| Net Receivables | $- | $1.43M | $1.11M | $110.00K | $10.00K |
| Inventory | $- | $- | $-1.11M | $1.25M | $107.00K |
| Other Current Assets | $2.56M | $1.35M | $8.35M | $1.26M | $132.00K |
| Total Current Assets | $248.04M | $284.58M | $335.12M | $385.44M | $36.23M |
| Property Plant Equipment Net | $3.63M | $4.63M | $5.56M | $5.12M | $71.00K |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $427.00K | $430.00K | $459.00K | $- | $212.00K |
| Total Non-Current Assets | $4.05M | $5.06M | $6.02M | $5.12M | $283.00K |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $252.09M | $289.64M | $341.14M | $390.56M | $36.52M |
| Account Payables | $2.19M | $1.94M | $3.02M | $1.62M | $1.40M |
| Short Term Debt | $- | $716.00K | $640.00K | $489.00K | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $6.28M | $6.97M | $7.11M | $3.17M | $931.00K |
| Total Current Liabilities | $8.46M | $9.62M | $10.78M | $5.28M | $2.33M |
| Long Term Debt | $1.53M | $2.33M | $6.10M | $6.29M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $-3.05M | $-3.14M | $45.50M |
| Total Non-Current Liabilities | $1.53M | $2.33M | $3.05M | $3.14M | $45.50M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $10.00M | $11.96M | $13.83M | $8.43M | $47.83M |
| Preferred Stock | $- | $- | $- | $390.56M | $45.36M |
| Common Stock | $6.00K | $6.00K | $6.00K | $6.00K | $1.00K |
| Retained Earnings | $-227.21M | $-177.63M | $-110.76M | $-47.46M | $-11.92M |
| Accumulated Other Comprehensive Income Loss | $475.00K | $62.00K | $-3.36M | $-244.00K | $156.00K |
| Other Total Stockholders Equity | $468.83M | $455.25M | $441.42M | $429.82M | $-44.91M |
| Total Stockholders Equity | $242.10M | $277.69M | $327.31M | $382.13M | $-11.31M |
| Total Equity | $242.10M | $277.69M | $327.31M | $382.13M | $-11.31M |
| Total Liabilities and Stockholders Equity | $252.09M | $289.64M | $341.14M | $390.56M | $36.52M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $252.09M | $289.64M | $341.14M | $390.56M | $36.52M |
| Total Investments | $222.91M | $260.60M | $303.89M | $85.50M | $33.71M |
| Total Debt | $1.53M | $3.05M | $3.69M | $3.63M | $- |
| Net Debt | $-21.03M | $-18.15M | $-22.81M | $-294.94M | $-2.38M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $22.56M | $30.33M | $45.70M | $29.40M | $21.20M | $27.94M | $27.20M | $28.81M | $26.50M | $42.52M | $119.65M | $287.31M | $298.57M | $357.66M | $370.84M | $400.69M | $2.38M | $-77.00K |
| Short Term Investments | $222.91M | $223.75M | $215.32M | $241.29M | $260.60M | $263.00M | $275.89M | $286.58M | $303.89M | $301.72M | $239.72M | $83.91M | $85.50M | $36.06M | $32.00M | $10.65M | $33.71M | $154.00K |
| Cash and Short Term Investments | $245.48M | $254.07M | $261.02M | $270.69M | $281.80M | $290.94M | $303.09M | $315.39M | $330.39M | $344.23M | $359.38M | $371.22M | $384.06M | $393.72M | $402.84M | $411.34M | $36.09M | $77.00K |
| Net Receivables | $1.26M | $- | $1.40M | $1.68M | $1.43M | $1.21M | $994.00K | $974.00K | $1.11M | $746.00K | $691.00K | $100.00K | $110.00K | $47.00K | $76.00K | $27.00K | $10.00K | $- |
| Inventory | $- | $- | $- | $- | $- | $-1.21M | $-994.00K | $-974.00K | $-1.11M | $- | $1.42M | $2.44M | $-110.00K | $- | $- | $- | $107.00K | $- |
| Other Current Assets | $1.30M | $3.17M | $2.43M | $1.52M | $1.35M | $6.00M | $4.92M | $6.12M | $3.62M | $3.51M | $1.65M | $2.55M | $1.26M | $1.42M | $1.86M | $298.00K | $132.00K | $- |
| Total Current Assets | $248.04M | $257.24M | $264.84M | $273.89M | $284.58M | $294.54M | $306.05M | $318.94M | $335.12M | $348.49M | $361.72M | $373.87M | $385.44M | $395.29M | $404.88M | $411.75M | $36.23M | $77.00K |
| Property Plant Equipment Net | $3.63M | $3.96M | $4.31M | $4.48M | $4.63M | $4.89M | $5.14M | $5.35M | $5.56M | $5.62M | $5.74M | $4.93M | $5.12M | $5.06M | $271.00K | $100.00K | $71.00K | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $239.72M | $- | $85.50M | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $427.00K | $427.00K | $429.00K | $427.00K | $430.00K | $437.00K | $444.00K | $452.00K | $459.00K | $466.00K | $-239.25M | $- | $-85.50M | $- | $- | $- | $212.00K | $-77.00K |
| Total Non-Current Assets | $4.05M | $4.39M | $4.74M | $4.91M | $5.06M | $5.33M | $5.58M | $5.80M | $6.02M | $6.08M | $6.21M | $4.93M | $5.12M | $5.06M | $271.00K | $100.00K | $283.00K | $-77.00K |
| Other Assets | $- | $- | $1 | $1 | $1 | $- | $- | $- | $- | $- | $-0 | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $252.09M | $261.63M | $269.58M | $278.79M | $289.64M | $299.87M | $311.63M | $324.74M | $341.14M | $354.57M | $367.93M | $378.80M | $390.56M | $400.35M | $405.15M | $411.85M | $36.52M | $- |
| Account Payables | $2.19M | $1.47M | $1.30M | $1.37M | $1.94M | $2.21M | $1.92M | $2.74M | $3.02M | $2.62M | $2.07M | $1.90M | $1.62M | $2.22M | $1.58M | $2.03M | $1.40M | $- |
| Short Term Debt | $800.00K | $778.00K | $757.00K | $736.00K | $716.00K | $697.00K | $677.00K | $658.00K | $640.00K | $622.00K | $604.00K | $503.00K | $489.00K | $475.00K | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $-697.00K | $-677.00K | $- | $- | $- | $- | $- | $-2.11M | $- | $- | $- | $- | $- |
| Other Current Liabilities | $5.48M | $5.18M | $4.34M | $4.99M | $6.97M | $9.49M | $9.53M | $5.64M | $7.11M | $7.17M | $4.71M | $3.08M | $3.17M | $2.81M | $1.82M | $1.67M | $931.00K | $- |
| Total Current Liabilities | $8.46M | $7.43M | $6.39M | $7.09M | $9.62M | $12.39M | $12.13M | $9.05M | $10.78M | $10.41M | $7.39M | $5.48M | $5.28M | $5.50M | $3.40M | $3.71M | $2.33M | $- |
| Long Term Debt | $1.53M | $1.74M | $3.89M | $2.14M | $4.67M | $5.04M | $5.40M | $5.76M | $6.10M | $6.44M | $6.76M | $6.02M | $6.29M | $6.55M | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $-1.95M | $- | $-2.33M | $-2.52M | $-2.70M | $-2.88M | $-3.05M | $-3.22M | $-3.38M | $-3.01M | $-3.14M | $-3.26M | $140.00K | $142.00K | $45.50M | $- |
| Total Non-Current Liabilities | $1.53M | $1.74M | $1.95M | $2.14M | $2.33M | $2.52M | $2.70M | $2.88M | $3.05M | $3.22M | $3.38M | $3.01M | $3.14M | $3.28M | $140.00K | $142.00K | $45.50M | $- |
| Other Liabilities | $- | $- | $1 | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $10.00M | $9.18M | $8.34M | $9.24M | $11.96M | $14.91M | $14.84M | $11.93M | $13.83M | $13.63M | $10.77M | $8.49M | $8.43M | $8.79M | $3.54M | $3.85M | $47.83M | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $400.35M | $405.15M | $411.85M | $45.36M | $- |
| Common Stock | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $1.00K | $- |
| Retained Earnings | $-227.21M | $-213.56M | $-200.52M | $-188.73M | $-177.63M | $-165.78M | $-150.00M | $-130.06M | $-110.76M | $-93.42M | $-75.72M | $-60.72M | $-47.46M | $-36.39M | $-25.07M | $-17.44M | $-11.92M | $- |
| Accumulated Other Comprehensive Income Loss | $475.00K | $914.00K | $-217.00K | $-167.00K | $62.00K | $-1.28M | $-2.00M | $-1.98M | $-3.36M | $-3.86M | $-2.31M | $-1.32M | $-244.00K | $-4.00K | $-12.00K | $2.00K | $156.00K | $-3.64M |
| Other Total Stockholders Equity | $468.83M | $465.10M | $461.98M | $458.45M | $455.25M | $452.02M | $448.78M | $444.85M | $441.42M | $438.22M | $435.19M | $432.35M | $429.82M | $427.95M | $426.68M | $425.44M | $-44.91M | $- |
| Total Stockholders Equity | $242.10M | $252.45M | $261.24M | $269.56M | $277.69M | $284.96M | $296.80M | $312.82M | $327.31M | $340.94M | $357.16M | $370.31M | $382.13M | $391.56M | $401.60M | $408.01M | $-11.31M | $-3.64M |
| Total Equity | $242.10M | $252.45M | $261.24M | $269.56M | $277.69M | $284.96M | $296.80M | $312.82M | $327.31M | $340.94M | $357.16M | $370.31M | $382.13M | $391.56M | $401.60M | $408.01M | $-11.31M | $-3.64M |
| Total Liabilities and Stockholders Equity | $252.09M | $261.63M | $269.58M | $278.79M | $289.64M | $299.87M | $311.63M | $324.74M | $341.14M | $354.57M | $367.93M | $378.80M | $390.56M | $400.35M | $405.15M | $411.85M | $36.52M | $-3.64M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $252.09M | $261.63M | $269.58M | $278.79M | $289.64M | $299.87M | $311.63M | $324.74M | $341.14M | $354.57M | $367.93M | $378.80M | $390.56M | $400.35M | $405.15M | $411.85M | $36.52M | $-3.64M |
| Total Investments | $222.91M | $223.75M | $215.32M | $241.29M | $260.60M | $263.00M | $275.89M | $286.58M | $303.89M | $301.72M | $479.45M | $83.91M | $85.50M | $36.06M | $32.00M | $10.65M | $33.71M | $154.00K |
| Total Debt | $2.33M | $2.52M | $2.70M | $2.88M | $3.05M | $3.22M | $3.38M | $2.88M | $3.69M | $3.84M | $3.98M | $3.52M | $3.63M | $3.75M | $- | $- | $- | $- |
| Net Debt | $-20.23M | $-27.81M | $-43.00M | $-26.52M | $-18.15M | $-24.72M | $-23.82M | $-25.93M | $-22.81M | $-38.68M | $-115.67M | $-283.80M | $-294.94M | $-353.91M | $-370.84M | $-400.69M | $-2.38M | $77.00K |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-49.59M | $-66.86M | $-63.31M | $-35.53M | $-8.28M |
| Depreciation and Amortization | $-5.60M | $537.00K | $406.00K | $129.00K | $5.00K |
| Deferred Income Tax | $- | $- | $- | $-77.00K | $-71.00K |
| Stock Based Compensation | $13.07M | $13.09M | $10.93M | $4.69M | $450.00K |
| Change in Working Capital | $-993.00K | $728.00K | $1.99M | $1.40M | $-811.00K |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $-1.22M | $-1.25M | $5.38M | $2.41M | $-413.00K |
| Other Working Capital | $226.00K | $1.97M | $-3.39M | $-1.02M | $-398.00K |
| Other Non Cash Items | $6.00K | $-6.05M | $-1.33M | $19.00K | $38.00K |
| Net Cash Provided by Operating Activities | $-43.10M | $-58.56M | $-51.32M | $-29.38M | $-8.67M |
| Investments in Property Plant and Equipment | $-340.00K | $-256.00K | $-918.00K | $-1.54M | $-76.00K |
| Acquisitions Net | $- | $- | $39.00K | $52.11K | $33.48K |
| Purchases of Investments | $-230.18M | $-224.70M | $-313.00M | $-86.26M | $-55.59M |
| Sales Maturities of Investments | $274.47M | $277.50M | $92.89M | $34.16M | $22.10M |
| Other Investing Activities | $- | $- | $39.00K | $-52.11K | $-33.48K |
| Net Cash Used for Investing Activities | $43.95M | $52.54M | $-220.99M | $-53.64M | $-33.56M |
| Debt Repayment | $- | $- | $- | $- | $44.53M |
| Common Stock Issued | $- | $724.00K | $662.00K | $254.27M | $1.00K |
| Common Stock Repurchased | $477.00K | $305.00K | $339.00K | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $513.00K | $724.00K | $235.00K | $124.94M | $1.00K |
| Net Cash Used Provided by Financing Activities | $513.00K | $724.00K | $235 | $379.21K | $44.53M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $1.36M | $-5.30M | $-272.07M | $296.19M | $2.30M |
| Cash at End of Period | $22.56M | $21.20M | $26.50M | $298.57M | $2.38M |
| Cash at Beginning of Period | $21.20M | $26.50M | $298.57M | $2.38M | $77.00K |
| Operating Cash Flow | $-43.10M | $-58.56M | $-51.32M | $-29.38M | $-8.67M |
| Capital Expenditure | $-340.00K | $-256.00K | $-918.00K | $-1.54M | $-76.00K |
| Free Cash Flow | $-43.45M | $-58.82M | $-52.23M | $-30.91M | $-8.74M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-13.65M | $-13.04M | $-11.79M | $-11.11M | $-11.84M | $-15.79M | $-19.94M | $-19.29M | $-17.34M | $-17.70M | $-15.00M | $-13.27M | $-11.06M | $-11.32M | $-7.64M | $-5.51M | $-3.85M | $-2.32M | $-1.44M | $-663.00K |
| Depreciation and Amortization | $149.00K | $-4.61M | $151.00K | $143.00K | $138.00K | $137.00K | $133.00K | $129.00K | $124.00K | $108.00K | $92.00K | $82.00K | $82.00K | $31.00K | $12.00K | $4.00K | $4.00K | $1.00K | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $3.11M | $-1.71M | $-1.40M | $- | $- | $- | $- | $- | $26.00K | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $3.47M | $3.12M | $3.30M | $3.18M | $2.72M | $3.22M | $3.72M | $3.43M | $3.08M | $2.87M | $2.62M | $2.36M | $1.56M | $1.24M | $1.24M | $647.00K | $421.00K | $15.00K | $10.00K | $4.00K |
| Change in Working Capital | $1.61M | $1.68M | $-1.35M | $-2.93M | $-1.99M | $-400.00K | $3.67M | $-553.00K | $-63.00K | $1.27M | $1.82M | $-1.04M | $160.00K | $1.85M | $-1.93M | $1.32M | $588.00K | $503.00K | $138.00K | $-2.04M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $1.01M | $1.02M | $-720.00K | $-2.52M | $-2.81M | $239.00K | $3.07M | $-1.75M | $408.00K | $3.17M | $1.61M | $200.00K | $-41.00K | $1.38M | $-301.00K | $1.38M | $- | $- | $- | $- |
| Other Working Capital | $605.00K | $660.00K | $-628.00K | $-411.00K | $823.00K | $-639.00K | $598.00K | $1.75M | $-471.00K | $-1.90M | $217.00K | $-1.24M | $201.00K | $1.85M | $-1.93M | $-60.00K | $588.00K | $503.00K | $138.00K | $-2.04M |
| Other Non Cash Items | $-1.44M | $3.31M | $2.75M | $4.27M | $3.98M | $8.00K | $10.00K | $-1.13M | $-888.00K | $-444.00K | $-33.00K | $33.00K | $14.00K | $30.00K | $22.00K | $-150.00K | $-2.00K | $-58.00K | $-13.00K | $40.00K |
| Net Cash Provided by Operating Activities | $-9.86M | $-9.55M | $-11.26M | $-12.44M | $-12.80M | $-14.53M | $-13.80M | $-17.42M | $-15.09M | $-13.90M | $-10.50M | $-11.83M | $-9.23M | $-8.16M | $-8.29M | $-3.70M | $-2.84M | $-1.86M | $-1.31M | $-2.66M |
| Investments in Property Plant and Equipment | $- | $16.00K | $-161.00K | $-195.00K | $-27.00K | $-53.00K | $-89.00K | $-87.00K | $-288.00K | $-310.00K | $-244.00K | $-76.00K | $-354.00K | $-968.00K | $-183.00K | $-33.00K | $-14.00K | $-62.00K | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $31.89K | $- | $-12.07K | $-19.82K | $768 | $63.08K | $39.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-64.37M | $-66.51M | $-53.63M | $-45.66M | $-74.15M | $-54.57M | $-62.37M | $-33.62M | $-61.01M | $-94.01M | $-157.98M | $- | $-49.91M | $-4.32M | $-26.93M | $-5.11M | $- | $-12.83M | $-3.51M | $-39.25M |
| Sales Maturities of Investments | $66.20M | $60.67M | $81.12M | $66.47M | $79.73M | $69.89M | $74.44M | $53.44M | $60.24M | $30.93M | $1.23M | $490.00K | $200.00K | $245.00K | $5.54M | $28.17M | $2.01M | $16.08M | $4.01M | $- |
| Other Investing Activities | $- | $- | $27.49K | $20.81K | $5.58K | $15.32K | $12.07K | $19.82K | $-768 | $-63.08K | $39.00K | $490 | $-49.70K | $-4.07K | $-21.39K | $23.06K | $2.01K | $3.25K | $501 | $-39.25K |
| Net Cash Used for Investing Activities | $1.83M | $-5.83M | $27.33M | $20.62M | $5.55M | $15.27M | $11.98M | $19.73M | $-1.06M | $-63.39M | $-156.96M | $414.00K | $-50.06M | $-5.04M | $-21.57M | $23.03M | $2.00M | $3.19M | $501.00K | $-39.25M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-200.00K |
| Common Stock Issued | $- | $-249.00K | $229.00K | $20.00K | $501.00K | $13.00K | $210.00K | $- | $130.00K | $151.00K | $225.00K | $156.00K | $193.00K | $30.00K | $5.00K | $254.27M | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $223.00K | $- | $- | $305.00K | $- | $- | $- | $339.00K | $- | $- | $- | $194.00K | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $263.00K | $1.00K | $229.00K | $20.00K | $501.00K | $13.00K | $210.00K | $- | $130.00K | $151.00K | $-202.00K | $156.00K | $193.00K | $30.00K | $5.00K | $124.71M | $1.00K | $- | $- | $89.46M |
| Net Cash Used Provided by Financing Activities | $263.00K | $1.00K | $229.00K | $20.00K | $501 | $13 | $210 | $- | $130 | $151 | $-202 | $156 | $193 | $30 | $5 | $378.98K | $1.00K | $- | $- | $44.53M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-7.76M | $-15.37M | $16.30M | $8.20M | $-6.74M | $745.00K | $-1.61M | $2.31M | $-16.02M | $-77.14M | $-167.66M | $-11.26M | $-59.09M | $-13.18M | $-29.86M | $398.31M | $-845.00K | $1.33M | $-806.00K | $2.62M |
| Cash at End of Period | $22.56M | $30.33M | $45.70M | $29.40M | $21.20M | $27.94M | $27.20M | $28.81M | $26.50M | $42.52M | $119.65M | $287.31M | $298.57M | $357.66M | $370.84M | $400.69M | $2.38M | $3.22M | $1.90M | $2.70M |
| Cash at Beginning of Period | $30.33M | $45.70M | $29.40M | $21.20M | $27.94M | $27.20M | $28.81M | $26.50M | $42.52M | $119.65M | $287.31M | $298.57M | $357.66M | $370.84M | $400.69M | $2.38M | $3.22M | $1.90M | $2.70M | $77.00K |
| Operating Cash Flow | $-9.86M | $-9.55M | $-11.26M | $-12.44M | $-12.80M | $-14.53M | $-13.80M | $-17.42M | $-15.09M | $-13.90M | $-10.50M | $-11.83M | $-9.23M | $-8.16M | $-8.29M | $-3.70M | $-2.84M | $-1.86M | $-1.31M | $-2.66M |
| Capital Expenditure | $- | $16.00K | $-161.00K | $-195.00K | $-27.00K | $-53.00K | $-89.00K | $-87.00K | $-288.00K | $-310.00K | $-244.00K | $-76.00K | $-354.00K | $-968.00K | $-183.00K | $-33.00K | $-14.00K | $-62.00K | $- | $- |
| Free Cash Flow | $-9.86M | $-9.53M | $-11.42M | $-12.63M | $-12.82M | $-14.59M | $-13.89M | $-17.51M | $-15.38M | $-14.21M | $-10.74M | $-11.90M | $-9.58M | $-9.13M | $-8.47M | $-3.73M | $-2.86M | $-1.92M | $-1.31M | $-2.66M |
Design Therapeutics Dividends
Explore Design Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Design Therapeutics News
Read the latest news about Design Therapeutics, including recent articles, headlines, and updates.
Design Therapeutics to Participate in Leerink's Global Healthcare Conference
CARLSBAD, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during Leerink's Global Healthcare Conference on Monday, March 10, 2025, at 1:40 p.m. ET in Miami.
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences:
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
Fuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the First Half of 2025 Friedreich Ataxia (FA) Program on Track to Initiate Phase 1 Single Ascending Dose, Healthy Volunteer Study in the First Half of 2025 Active Research Pipeline Advancing with Programs in Myotonic Dystrophy Type-1 (DM1) and Huntington's Disease (HD) Well-Capitalized with Cash and Securities of $254.1 Million to Fund Operations Through Up to Four Potential Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced its third quarter 2024 financial results and reviewed anticipated upcoming program milestones for its portfolio of GeneTAC™ candidates.
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet
The consensus price target hints at a 39.7% upside potential for Design Therapeutics (DSGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients Progressing GeneTAC TM Pipeline Programs in Huntington's Disease (HD) and Myotonic Dystrophy Type-1 (DM1) to Development Candidates Cash and Securities of $270.7 Million Support Multi-Year Operating Runway and Advancement of Up to Four Programs to Clinical Proof-of-Concept CARLSBAD, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced first quarter 2024 financial results along with recent business highlights and upcoming milestones.
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conference on Wednesday, May 15, 2024, at 11:30 a.m. ET in New York.
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 19, 2024, at 4:30 p.m. ET to discuss its fourth quarter and full year 2023 financial results and provide a comprehensive portfolio update.
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
Seasoned Biotech Executive Pratik Shah Appointed as Chief Executive Officer to Lead Company Turnaround Current Cash and Securities of ~$290M Support Extended Five-Year Operating Runway Through 2028 Revised Corporate Strategy with Realignment Towards Long-Term Growth to be Presented in Early 2024; Additional Details to Follow CARLSBAD, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today reported third quarter 2023 financial results.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
NEW YORK , Oct. 9, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). Such investors are advised to contact Robert S.
Design Therapeutics stock plunges on trial results for neuromuscular disease treatment
Shares of Design Therapeutics Inc. DSGN dropped 45% in premarket trading Tuesday after the biopharma company reported mixed results from an early-stage trial of a treatment for Friedreich ataxia, a genetic neuromuscular disease. The phase 1 trial of the treatment, DT-216, confirmed clinical activity in patients with the disease but also found injection-site reactions, the company said in a release late Monday.
Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
DT-216 Resulted in a Significant Increase in FXN mRNA Levels in Skeletal Muscle of FA Patients Treatment Generally Well-Tolerated; Injection Site Reactions Attributable to Current Formulation Composition Design Plans to Proceed with an Improved DT-216 Formulation and Initiate a Multiple Dose Phase 1 Clinical Study in the Second Half of 2024 Conference Call and Webcast to be Held Today at 4:30pm ET CARLSBAD, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported initial results from the company's Phase 1 multiple-ascending dose (MAD) clinical trial of DT-216 in patients with Friedrich ataxia (FA).
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
CARLSBAD, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported that management will present at the 2023 Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 3:30 p.m. ET in NYC.
Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
Treatment with DT-168 Eye Drops Reduced Nuclear Foci and Significantly Improved Mis-Splicing In Vitro Company On-track to Submit Investigational New Drug Application for DT-168 in the Second Half of 2023 CARLSBAD, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that preclinical data for the company's novel GeneTAC™ small molecule, DT-168, an eye drop being developed for the treatment of Fuchs endothelial corneal dystrophy (FECD), will be presented during an oral session at the Association for Research in Vision and Ophthalmology 2023 Annual Meeting (ARVO 2023), which is being held in New Orleans from April 23-27, 2023.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for DSGN.